小分子降解剂结合物:评估链接器的结构-活动关系,以克服PROTAC交付中的体内障碍
Shiwei Song1, Weina Jing1, Lei Peng1
1Department of Pharmaceutical Engineering, School of Pharmaceutical Sciences, Wuhan University, Wuhan, Hubei 430071, China.
Journal of medicinal chemistry
|August 15, 2025
概括
在小分子降解合物 (SMDCs) 中优化链接器化学可以改善蛋白解向仿真体 (PROTACs),用于精确的癌症治疗. 新型链接剂增强了稳定性和向性,使得较低剂量的瘤增长能够被有效地阻止.
科学领域:
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
- 在瘤学瘤学.
背景情况:
- 精确控制蛋白质溶解对于向蛋白质溶解的嵌合体 (PROTACs) 至关重要,以尽量减少组织外的毒性.
- 小分子降解合物 (SMDCs) 具有优势,但由于链接器化学缺陷,它们往往受到药物动力学限制,阻碍了体内应用.
研究的目的:
- 研究链接结构对体内因子的影响,如血清稳定性,血液保留,受控的PROTAC释放,向性和效力.
- 开发一个优化的链接器,以提高SMDC在生物体中的性能.
主要方法:
- 结构-活动关系 (SAR) 研究分析链接效应.
- 开发一种新型的cathepsin-responsive/carbamate连接器,使用长循环CBB延伸器.
- 使用开发的链接器结合cRGD和GNE-987 PROTAC.
主要成果:
- 这种新型链接器表现出卓越的准能力,长期稳定性和有利的药理动力学.
- 类药物结合物实现了选择性,抗原依赖的蛋白解.
- 在体内观察到明显的瘤生长停止,剂量低于传统的SMDCs和自由的PROTACs.
结论:
- 链接器优化对于改善SMDCs的体内疗效和药理动力学特性至关重要.
- 链接器优化的SMDC降解剂代表了精准医学的一个有希望的方法,使得针对性癌症治疗具有更高的安全性和有效性.
相关概念视频
Ligand Binding and Linkage
4.9K
Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked. In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence...
4.9K
Ligand Binding Sites
13.2K
Proteins are dynamic macromolecules that carry out a wide variety of essential processes; however, the activities of most proteins depend on their interactions with other molecules or ions, known as ligands.
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
13.2K
Structure-Activity Relationships and Drug Design
1.0K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.0K
Prodrugs
2.8K
Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.
Prodrugs help overcome...
Prodrugs help overcome...
2.8K
Phase II Conjugation Reactions: Overview
313
Conjugation, a key component of phase II biotransformation reactions, is a vital process in drug detoxification. It involves transferring endogenous substances like glucuronic acid, sulfate, and glycine to drugs or their metabolites formed in phase I reactions. These conjugation reactions, often catalyzed by specific enzymes, transform potentially harmful metabolites into inactive, water-soluble forms easily excreted in urine or bile. By enhancing polarity and eliminating pharmacological...
313


